center medical collaboration, was received well, it took ten years before the consensus was reached that HLA matching was helpful m the unrelated donor-recipient combinations {Transplantation Proceedings, 1977) . In retrospect, this delay can be explained by the following considerations 1. Many of the early studies had, because of the extreme polymorphlsm of HLA, far too few "good" matches-i.e., HLA-A-and-5-identical matches-to allow for a meanmgful Interpretation of the data 2. The influence of hnkage dysequilibnum was msufficiently taken into account in most studies. 3 In the unrelated donor-recipient combination, where complete HLA identity IS rare, lf it occurs at all, helper or suppressor mechanisms, or both, can be activated that make a simphstic Interpretation of the number of HLA-A and -B mismatches redundant.
That HLA-A and -B matching does improve kidney allografting is illustrated by Fig. 1 , which presents the results obtamed in the organexchange organizaüon Eurotransplant in the penod 1972-1977 and concerns over 3000 first cadavenc transplants . The data show that 5 years after transplantaüon, grafts with no HLA-A and -B imsmatches do over 15% better than grafts mismatched for three or four anügens. The difference is statistically significant from 6 months posttransplant onward and meanmgful both for the patient and in the context of the cost-benefit aspects of the treatment of end-stage renal failure.
Two further pomts can be deduced from Fig. 1 as well. The first is that about one third of the transplants fail withm the first 3-6 months after transplantaüon, and the second is that although the grafts mismatched for three or four HLA-A and -B anügens do on the average less well tban those that were better matched, some of these three-to fouiantigen-mismatched grafts do quite well even after 5 years In other words, even a good HLA-A and -B match is no guarantee of good funcüon, and by contrast, good graft function can occur vis-ä-vis a very poor HLA match It is both of great theoretical importance and of great practical importance to understand the mechanism by which these mismatched grafts are able to survive Recently, several variables have been identified that apart from HLA-A and -B matching per se are able to significantly influence kidney graft survival. We will discuss three of these Blood transfusion and HLA-DR matching have a graft-protecüng effect, while lncompaübihty for MHC-restncted and MHC-nonrestncted non-HLA anügens can lmpair graft survival. Figure 1. Kidney-graft survival of over 3000 consecutive transplants performed in collaboration with the Eurotransplant organ-exchange organization. Note that after 6 months, there IS an 8% difference, and after 60 months a 15% difference, between the best-and poorest-matched grafts. From Persijn et al. (1979) .
Blood Transfusion
Opelz et al. (1973) were the first to present significant evidence not only that blood transfusion can cause immunization, which endangers graft survival, but also that it can prolong graft survival. Their observation has been confirmed by most workers, including our own group . Furthermore, a randomized prospective study in rhesus monkeys that received five blood transfusions over a 3-month period prior to transplantation and Standard immunosuppression after transplantation showed a significant fourfold Prolongation of graft survival ( Fig. 2) (van Es et al., 1977) .
In Leiden, a retrospective study by van Hooff et al. (1976) showed that patients who had received one blood transfusion appeared to do better than patients who had received none. Next, Persijn et al. (1979) evaluated the role of the number of blood transfusions in kidney-graft survival in 895 patients who had received a kidney transplant between January 1, 1967, and March 1, 1977. The transfusion history was checked by scrutinizing the relevant documents (e.g., medical history, blood bank files, hemodialysis reports) and by personal Interviews with the patients or their relatives or both. For female patients, the number of pregnancies et al (1977) and abortions was recorded. In this way, these authors found 68 male and 6 female patients who had never been transfused or been pregnant before transplantaüon. None of them had preformed leukocyte antibodies in their serum Similarly, 27 male and 3 never-pregnant female patients were identified who had received only a Single blood transfusion, a third of them 1 year or more before transplantation. Some of these patients remembered the exact date of transfusion, and this was checked and confirmed in the blood bank records. None of these patients had detectable antileukocyte antibodies in their sera. The composition of the transfusate (e.g., whole blood, washed erythrocytes, filtered blood) was not taken into account because accurate Information on this was not available. All patients in this analysis, except one patient in the nontransfused group, had received blood transfusions dunng transplantation varying from 1 to more than 5 units. As can be seen in Fig. 3 , the patients who had received one blood transfusion did extremely well (80% graft survival at 6 months after transplantation), while those who had received no blood transfusion did very poorly indeed. On the basis of these findings, a prospective tnal was started in Holland in which lt was planned to compare the graft-protecting effect of one pretransplant transfusion of leukocyte-poor blood with three such transfusions. The precise way in which the blood was to be prepared was not specified. Most centers gave "washed" leukocyte-poor blood, but a few used cotton-wool-filtered blood, which for all pracücal purposes IS leukocyte-free (Diepenhorst et al., 1972) As IS shown in Fig. 3 , this prospective study confirmed the retrospective study with respect to the graft-protecting effect of one transfusion of leukocyte-poor blood. In contrast, the patients transfused with cotton-wool-filtered leukocyte-free 
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FOLLOW-UP TIME IN DAYS Figure 3 . Graft survival in relation to a single pretransplant blood transfusion. Only transfusions of leukocyte-poor blood had a graft-protecting effect. From Persijn et al. (1978) .
blood did as poorly as the nontransfused patients. We conclude from these data that a small amount of buffycoat cells given once before transplantation induces significant graft protection and that buffycoatfree erythrocytes will not do so. Others have suggested that peroperative blood transfusions without preoperative ones can cause graft facilitation (Stiller et al., 1978) . During the last two years, almost all peroperative blood transfusions to the patients shown in Fig. 3 have been leukocytefree. However, before that date, leukocyte-poor blood was often given. Its effect on graft survival is under study. Because of the very poor overall graft survival in the group of patients who received no blood transfusions before transplantation, it appears unlikely to us that peroperative blood transfusions with leukocyte-poor blood are as effective as preoperative ones. On two points, our findings are at variance with those of others. First, although almost all authors agree that patients who had received pretransplant blood transfusions do better than those who did not, most centers find that graft survival in the nontransfused group is not 20-30% as we observed (Fig. 3 ), but 40-60% at 1 year Opelz and Terasaki, 1978) . We have no good explanation for this discrepancy. Inadequate inventorying of the blood-transfusion history might be an explanation for some but not for all studies. The poorer graft survival in our nontransfused-patient group is unlikely to be due to poorer HLA matches as compared to the other studies. This discrepancy thus focuses our attention on yet another unknown variable determining the outcome of kidney transplantation. Second, another discrepancy lies in the number of blood transfusions given. Although some centers (Morris, personal communication) have confirmed our Unding that one blood transfusion protects graft survival, others have not (Opelz and Terasaki, 1978) . This is another unexplained discrepancy. Preliminary findings from our group suggest that one blood transfusion is especially effective in the group of patients who received a one-DR-antigen-mismatched graft (see below). Because Opelz's patient material is racially more heterogeneous than the Dutch material, this observation might be relevant.
The mechanism by which blood transfusion protects graft survival is unknown. In all probability, this mechanism is different when many blood transfusions have been given as compared to the Situation in which only one or a few were given. Many blood transfusions will induce cytotoxic HLA antibodies in many patients. Those who do not form cytotoxic HLA-Α and -B antibodies are so-called "nonresponders." Graft survival in this group is known to be good. The term nonresponder is a misnomer, because these patients do form antibodies (anti-HLA-DR or other) that might be enhancing (Iwaki et al., 1978; Thompson et al., 1976) . Those who have formed cytotoxic anti-HLA antibodies will receive kidneys from donors who lack the corresponding antigens. It isassumed but not proven that such recipients cannot easily form immunity against other HLA antigens, and thus incompatibility for these will not influence graft survival.
This selection phenomenon cannot play a role when only one blooc transfusion has been given because in such cases, no antibodies or onl; weak antibodies in only a few recipients are formed. Whether the improved graft survival is due to the induetion of suppressor cells, broad reacting enhancing antibodies, or another mechanism is as yet unclear
In conclusion, almost everybody agrees that blood transfusion cai improve graft survival, but there is no agreement on the optimal numbe of blood transfusions to be given, the time interval between transfusion and transplantation, or even the way in which the blood should be prepared.
HLA-DR Matching
Almost from the beginning of clinical kidney allografting, evidence has been accumulating that indicated that a low or negative mixedlymphocyte culture (MLC) test was indicative for good transplant prognosis. This was in itself an important impetus to develop methods of typing the HLA-D determinants, which are the strengest Stimulus in the MLC test (Transplantation Proceedings, 1977) . The methods all used the basic MLC test or variants of it. However, because the MLC test is so time-consuming, it is suitable only for selection of living donorrecipient pairs.
Thus, a method was developed that would aüow rapid identification of //LA-Z)-identical donor-recipient pairs and that could be applied to cadaveric donors. Α systematic search for antibodies that could recognize the HLA-D determinants was begun. This effort was successful, and antibodies were identified that allowed the recognition of HLA-D antigens or determinants closely linked to them (Fig. 4) . The main topic of the 7th Histocompatibility Workshop was the recognition of these so-called "HLA-DR determinants" (Histocompatibility Testing 1977) .
To assess the importance of HLA-DR matching in kidney transplantation, DR typing was performed on peripheral-blood cells of the recipient and frozen spieen cells from the corresponding kidney donor . Figure 5A shows the influence of DR matching alone and Fig. 5B the influence of DR matching combined with (partial) matching for the HLA-A and -B antigens. Although the numbers are small and this is a retrospective study, the study strongly suggests that (1) even matching for one HLA-DR determinant can significantly reduce early graft loss (cf . Fig. 1) ; and (2) matching for HLA-DR combined with partial matching for the HLA-A and -B antigens might further improve prognosis; and (3) matching for both DR antigens appears to result in good graft survival as well, but here the numbers are too small for meaningful conclusions.
Other groups have done similar studies. Α summary of the total of the published European data is presented in Table 1 (Ting and Morris, 1978; Martins-da-Silva et al, 1978; Albrechtsen et al., 1978) . It is clear that although the number of //LA-Di?-identical grafts is small, they give the highest percentage of functioning grafts in all series, and that the percentage of functioning grafts in the two-DR-antigens-mismatched group is the lowest. Problems arise with the one-DR-antigen-mismatched group because it is often imclear from publications of others whether these include potential incompatibilities or not (e.g., an HLA-DRwl/-donor transplanted onto an HLA-DRwl/2 recipient). With this restriction, the available data show that in the majority of transplants performed in Europe, matching for two and also for one HLA-DR antigen improves graft survival significantly. The improvement by matching for two HLA-DR determinants was expected because earlier studies had shown that a low or negative MLC test between parent-child or unrelated donorrecipient pairs improved graft survival (Jeannet, 1970; Hamburger et al., 1971; Cochrum et al, 1973) . Although not all HLA-D-or -£>/?-identical combinations lead to a negative or low MLC test, the majority do°o Figure 5A . Kidney-graft survival and matching for HLA-DR antigens alone. The top curve represents grafts with one mismatch at the DR locus, the middle curve, ßÄ-identical grafts, the bottom curve, grafts with two mismatches at the DR locus. The figures above the curves are the numbers of grafts at nsk. 
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Figure 5B Kidney-graft survival and matching for HLA A, -B, and DR anügens The top curve represents £>Ä-identical grafts with one or fewer mismatches at theA orB locus, the middle curve, grafts with one or fewer mismatches at the Α or Β locus and one mismatch at DR, the bottom curve, other grafts From Persyn et al (1978) (Termijtelen et al., 1977) , and this could explain the good results in the //LA-£)i?-identical group. On the other hand, combinations that are mismatched for one HLA-DR determinant are always MLC-positive. Why is it then that grafts mismatched for one HLA-DR antigen do so well? From the point of immunogenetics, this is of course heresy: a difference of an antigen -Λ between donor and recipient has always been considered to be dominant Jt over sharing an antigen, and the first question we have to answer is whether our observation that a one-DR-mismatched graft does so well is correct.
Corroboratory evidence was obtained from a study by van Hooff et al. (1974) , who had already shown that matching between unrelated individuals for an HLA-A and -B antigen combination in strong linkage ; dysequilibrium with an HLA-DR determinant, such as the HLAAl,B8,DRw3 combination, was associated with an improved graft survival. The percentage of graft survival exceeded that obtained for the overall survival in patients who were matched for two HLA-A and -B antigens that were not in linkage dysequilibrium. Thus, in this Situation, donor and recipient were also matched, although indirectly, for one DR antigen (and mismatched for the other), and this was associated with better graft survival. There also exists corroborating evidence that one-DR-mismatched grafts do well in the parent-child data. They do much better than those differing by two DR antigens; in fact, in Holland they do as well as //LA-identical siblings (Persijn, unpublished observations) . Others have made similar observations (Thompson et al., 1977a; Oliver et al., 1972; Fotino and Allen, 1972; Cochrum et al., 1973; Beizer et al, 1974; Dausset et al., 1974; Dausset and Hors, personal Communications; Stenzel et al., 1974; Festenstein et al., 1976) .
These observations reinforce our finding that matching for only one DR determinant can significantly improve graft survival. It is also clear that the data available are limited and in part retrospective and that prospective trials are indicated. This will be one of the main topics in the forthcoming 8th Histocompatibility Workshop. This is especially urgent because data from Los Angeles (Terasaki) and more recently from European studies have failed to show a significant improvement of graft survival in the one-DR-antigen-mismatched group, We cannot yet exclude, of course, the possibility that it is not DR we should match for but another closely linked locus, e.g., HLA-D. Interracial transplants will be very useful in evaluating this (Troup et al., 1978) .
It should be stressed that with the exception of two individuals, all the recipients in this study who received a kidney mismatched for one DR determinant had been transfused. Although this might be an important prerequisite, confiicting data exist on this point. Swedish workers found v that graft survival in parent-child combinations was good only lf the recipient had been transfused before transplantation (Brynger et al., 1977) . The Dutch data are consistent with this, although a control group of nontransfused recipients IS lackmg. By contrast, Solheim et al. (1977) and Opelz and Terasaki (1978) did not find a graft-protecüng effect of blood transfusions in parent-child combinations, and furthermore Morris Claims that the beneficial effect of DR matching is most clear in the nontransfused group (Morris, personal Communications) .
In an attempt to clanfy the mechamsm by which matching for one or two DR determinants overndes the effect of incompatibility for other anügens, we investigated whether these findings on DR matching and graft survival had anm vitro correlate. Both MLC tests and cell-mediated lymphocytotoxicity (CML) tests (after in vitro pnming) were studied. Lymphocytes were taken from patients 3-18 months after transplantation, and these were reacted with the splenocytes from their specific kidney donor, which had been stored in liquid nitrogen. The lymphocytes of slightly more than half the patients who had functioning grafts had a negative CML test, while they were reactive with lymphocytes from random donors. We could actually show that the CML test changed from positive before transplantation to negative after transplantation (Fig. 6) .
Our findings show stnkmg similanty to observations of , who studied CML reactivity in parent-child combinations, and of Womgeit and Pichlmayr (1977) , who studied cadavenc-kidneytransplant recipients. The new data from these longitudinal studies presented here show that the increment of percentage kill against donor as measured in CML can be negative a few weeks and not many years after transplantation. In other words, a decreasing CML may be associated with good survival and an increasing CML with poor survival.
Although our prelimmary studies suggested that CML nonreactivity occurred most frequently in the one-DR-mismatched group, our recent, more extensive, data have failed to confirm this. In other words, CML nonreactivity and DR matching appear not to be significantly associated.
In summary, the current picture emerges as follows· 1. Matching, for two and for one DR determinant improves graft survival to about 80% at 1 year. It should be stressed that almost three fourths of our patients were grafted with a kidney that carned zero or one HLA-A or-B mismatch only. Our data suggest that DR matching remforces but does not replace HLA-A and -B matching. 2. Α fall in donor-specific CML develops in at least half the patients following transplantation. The ongin of this phenomenon is under study Figure 6 Longitudinal CML study after a planned blood transfusion (V) and kidney transplantation Top CML reactivity against the specific kidney donor, bottom percentdge lysis against a control cell The follow-up time in days IS on the abscissa
Incompatibihty for Non-HLA Determmants
Incompatibilities for determmants outside HLA will influence graft survival as well. The first example of this was the deletenous effect of ABO-blood-group incompatibihty on graft survival (Starzl et al , 1964) . More recently, French workers have noticed that kidneys transplanted in Lewis-blood-group-negative recipients have a poorer prognosis than Lewis-positive recipients, presumably because of incompatibihty for the Lewis system (Οποί et al , 1978) This observation could explain why grafts from Cauca»oid donors, who have a high frequency of Lewispositive individuals, do so poorly lf transplanted in patients of negroid descent, who are often Lewis-negative Very little attention has so far been paid to cell-or tissue-hnespecific Systems outside that of the HLA-DR antigens. However, Moraes and Stastny (1977) have ldentified a multiallelic system that occurs on both endothelial cells and monocytes (Table 2) . Paul et al. (1979) and Claas et al. (1979) have independently identified similar antibodies and have shown that these play in all probability an important role in rejection of both kidneys (Table 3) and bone-marrow grafts (Table 4) . Little is yet known of the precise conditions under which these antibodies can be formed, but they can arise after repeated transfusions or kidney-graft rejection, or both. It is also uncertain whether the locus or loci coding for the determinants recognized by them lie in or near the HLA complex, but Thompson et al. (1977b) have identified a polymorphic locus not linked to HLA coding for determinants on monocytes, endothelial cells, and neutrophils. Now that the technical difficulties originally met in the recognition of the monocyte antigens have been solved and their clinical relevance has been established, it will not take long before a more complete description of the system will be possible.
Another point that has to be taken into account is that of MHC restriction, which is dealt with more fully in Chapter 3. In brief, MHC restriction implies that incompatibility for a non-MHC determinant will be recognized by the recipient only if donor and recipient share at least part of the HLA-Α and -B determinants. To describe this, the term "dual recognition" was coined, by which is meant that both the non-MHC determinant and the seif HLA-A or -B antigens have to be recognized on the target cell (Zinkernagel and Doherty, 1974; Shearer, 1974) . The dualrecognition phenomenon was first described in the mouse, but it has also been shown to exist in man. The non-MHC determinants concern both intrinsic determinants such as H-Y and extrinsic or acquired antigens such as those of choriomeningitis or influenza virus. " Adapted from Paul et al. (1979) . Two patients are excluded, one because of ABO incompatibility and another because donor kidney tissue was not available. b CEAb present dunng rejection episodes. skin-graft model to be a transplantation barrier of medium strength (von Boehmer et al., 1977; Hurme et al., 1978) . In man, it has been shown that MHC-restricted anti-H-Y immunity can occur in vivo and in vitro using an indirect CML assay. It is of interest that so far MHC restriction has been found only for the HLA-A2 and -B7 antigens, which belong to the most immunogenic antigens of the HLA System. That this HLArestricted anti-H-Y immunity is of clinical importance is not definitively proven, but suggestive evidence supporting this notion has been presented for both kidney and bone-marrow allografts (Table 5) (Storb et al., 1977; Goulmy et al., 1978) . So far, such Information is available only for H-Y in man, but it is likely that this will be true for other non-MHC determinants as well, as has been discussed by one of us (Bradley and Festenstein, 1978, Bradley, in prep ) . An effect on graft survival of these non-MHC lncompatibilities will be present only lf donor and recipienl share at least some of the HLA-A or -B determinants. In other words, IJ donor and recipient share none of the HLA-A or -B determinants, the effect of these determinants might be negligible. This could explain why grafts mismatched for three or four HLA-A and -B antigens sometimes do relatively well. These individuals, although mismatched for HLA-A and -B, would suffer no adverse effect from non-HLA incompatibihties lf these show MHC restnction. In contrast, recipients of giafts wel. matched for HLA-A and -B would recognize most of the HLA-A-or -B restncted minor histocompatibility antigens. All this concerns dual recognition in which a non-MHC and ar MHC determinant participate. There IS, however, no reason to exclude the possibihty that dual recognition could also exist between two differen classes of MHC determinants. Α good case in point is the targets of tht CML reaction in HLA, the so-called "CD determinants." Prehminarj studies indicate that these are closely associated with the HLA-A and Β determinants but not identical to them (Fig. 7) . That this is indeed < case of HLA-B restnction is suggested by the fact that not a singh positive reaction was found lf neither Bw35 nor Bw53 was present. W( assume that to recognize these CD determinants, either Bw35 or Bw5 must be present. The MHC-restncted non-HLA determinants have beei named by Bradley the histocompatibility-associated membrane or (HAM minor antigens, the MHC-restncted HLA determinants, the HAM majo antigens .
MHC-restricted immunity against H-Y has been shown in the mouse
We have discussed the role of dual recognition in connection witl· the HAM minor and major antigens so far only in relation to the effector phase of the homograft response. That IS the only part for which some limited evidence is available. MHC-restricted immunity against non-HLA and HLA determinants does not occur spontaneously; in other words, it must be induced in vivo. Almost no systematic Information is available on the conditions under which MHC-restricted immunity can arise, but it is assumed that this Stimulus must be strong; i.e., it will occur only after many blood transfusions or graft rejection, or both. In practice, this means that MHC-restricted immunity will arise only when the recipient is repeatedly challenged with MHC and non-MHC incompatibilities, in which the MHC incompatibilities provide "help" for the recognition of the non-MHC incompatibilities.
Discussion and Conclusions
We certainly have not been able to give an all-encompassing answer to the question why some poorly matched kidneys survive so well, but we have made a preliminary inventorying of the different factors other than HLA-A and -B matching that (might) influence graft survival.
In our opinion, blood transfusion is one of the prime variables. Ever after a Single pretransplant blood transfusion, the homograft reactior seems to be significantly weakened. The mechanism by which this occur« is unclear, but could be due to the induction of an (aspecific?) suppresso cell or to the activation of cell clones that an capable of forming enhancing antibodies, or to both. On first sight, i might seem improbable that a Single blood transfusion would be capabk of inducing antibodies that would be able to enhance the survival ο kidney grafts from almost any donor. Immunization against the deter minants of a Single locus, e.g., HLA-DR, is incompatible with th< induction of such broad-reactive enhancing antibodies . However, if we take the MLC Inhibition test as an in vitn analogue of in vivo enhancement, then a possible explanation offers itsel (Albert, personal communication; Bach, personal communication). Jon ker and van and Albrechtsen et al. (1977) have shown tha not only anti-DR but also anti-HLA-A and -B antibodies can inhibit th MLC reaction. The question then becomes what the chance is that blood-transfusion donor will differ for one of the HLA-A, -B, -C, or -DJ antigens with the recipient, while sharing it with the kidney donoi Assuming that cross-reacting antigens can be counted as one, then it ca be calculated that in about 75% of the recipients of one blood transfusior the blood-transfusion donor will share a cross-reacting HLA-A, -B, or DR antigen with the kidney donor, while this antigen is absent in th recipient. This percentage of "enhanced" grafts can be added to th 20-30% of the grafts that do well even if no blood transfusion is give and would then result in the high percentage of well-functioning grafi we have indeed found. This hypothesis is open to experimental proo because one would expect that such antibodies would be detectable. We have not been able to demonstrate their presence with the complementdependent cytotoxicity test, but because more sensitive test Systems have not yet been tried, their existence cannot be formally excluded.
If only one blood transfusion is given, we assume, but again have no / % hard data to evidence, that immunization against MHC-dependent or ' -~ Jt independent non-HLA antigens will not frequently occur. There are as yet insufficient data to assess the importance of (partial) matching for HLA-DR in the nontransfused patient or after only one blood transfusion.
---If, on the other hand, many blood transfusions have been given before transplantation, immunity against HLA and non-HLA determinants will often ensue, and depending on the match of donor and 1 recipient, this will influence graft survival. In our patient material, partial matching for HLA-DR improves graft survival significantly in this group of patients. CML nonreactivity can develop in a period of weeks posttransplantation independently of the DR match. This CML nonreactivity might be due to the induction of suppressor cells or clonal inactivation or both.
Many of the still-existing discrepancies might disappear if füll characterization of the antibodies formed after blood transfusion were carried out routinely. This can be quite difficult and is certainly not possible if only a Standard complement-dependent cytotoxicity test is used. It is depressing to come to the conclusion that more than 20 years after it was shown that non-complement-binding antibodies can cause enhancement instead of graft rejection, almost all centers study their patients' sera only with complement-dependent cytotoxicity assays. Α complete analysis of the methods that should be used to detect antibodies in the sera of transplant recipients and to determine their specificity has yet to be made. Such an analysis will, apart from the technical problems, also be hindered by our incomplete knowledge of the immunogenetics of the HLA and especially the non-HLA Systems. Α beginning of the inventorying of the non-HLA Systems that are relevant in kidney transplantation and the way they exert their influence has been made. It should be stressed that it is so far only a beginning.
